MYL's subsidiary obtains drug registration certificate for sodium hyaluronate eye drops
MYL's wholly-owned subsidiary, Jiangxi MYL Meikang Pharmaceutical Co., Ltd., recently obtained the sodium hyaluronate eye drops drug registration certificate issued by the National Medical Products Administration. This approval will enrich the company's ophthalmic product line and enhance market competitiveness
According to the Zhitong Finance APP, MYL (600993.SH) announced that its wholly-owned subsidiary Jiangxi MYL Meikang Pharmaceutical Co., Ltd. (referred to as "MYL Meikang") has received the Drug Registration Certificate (Certificate No.: 2025S01677) for Sodium Hyaluronate Eye Drops [Specification: 0.3% (0.4ml:1.2mg)] approved and issued by the National Medical Products Administration.
The approval of this Drug Registration Certificate will help further enrich the company's ophthalmic product line and enhance the market competitiveness of the company's products
